Natalie Holles

Natalie is Chief Executive Officer of Third Harmonic Bio. She has more than 20 years of executive leadership, business development, corporate strategy, and commercial experience gained in a range of therapeutic areas.

Prior to Third Harmonic, Natalie served as President and Chief Executive Officer of Audentes, an Astellas company. She joined the company as Senior Vice President and Chief Operating Officer in August 2015 and was subsequently promoted to President and Chief Operating Officer in May 2018, and then to President and Chief Executive Officer in January 2020. Prior to joining Audentes, Natalie served as Senior Vice President, Corporate Development at Hyperion Therapeutics, Inc. (acquired by Horizon Pharma in 2015). Before that, she provided executive-level strategy and business development advisory services to a number of privately held biopharmaceutical companies. Earlier in her career, Natalie served as Vice President, Business Development at KAI Pharmaceuticals, Inc. (acquired by Amgen in 2012) and held corporate development and commercial roles at InterMune, Inc. (acquired by Roche in 2014) and Genentech, Inc.

Natalie holds an AB in human biology from Stanford University and an MA in molecular, cellular and developmental biology from the University of Colorado, Boulder, where she was a Howard Hughes Medical Institute predoctoral fellow.

CEO, Third Harmonic Bio


Join our email list to receive exclusive offers

Opt In